Announcements Trials

Browse Landscape

Phase

Phase NA 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 92 Breast Neoplasms 86 Neoplasms 79 Prostatic Neoplasms 50 Lung Neoplasms 44 Neoplasm Metastasis 40 Colorectal Neoplasms 37 Leukemia, Myeloid, Acute 32 Pain 27 Head and Neck Neoplasms 25 Colonic Neoplasms 25 Multiple Myeloma 24 Ovarian Neoplasms 23 Lymphoma 23 Carcinoma, Hepatocellular 23 Pancreatic Neoplasms 22 Lymphoma, Follicular 21 Melanoma 20 Leukemia 20 Rectal Neoplasms 19 Lymphoma, Non-Hodgkin 19 Urinary Bladder Neoplasms 17 Recurrence 17 Stomach Neoplasms 15 Lymphoma, Large B-Cell, Diffuse 15 Leukemia, Lymphocytic, Chronic, B-Cell 15 Squamous Cell Carcinoma of Head and Neck 13 Precursor Cell Lymphoblastic Leukemia-Lymphoma 13 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13 Leiomyoma 13

Interventions

brolucizumab 1 aflibercept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Terminated × Macular Degeneration × Clear all

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡